180 related articles for article (PubMed ID: 2756462)
1. Ovarian epithelial tumors of low malignant potential.
Chien RT; Rettenmaier MA; Micha JP; DiSaia PJ
Surg Gynecol Obstet; 1989 Aug; 169(2):143-6. PubMed ID: 2756462
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
3. Role of intervention surgery in stage III-IV epithelial ovarian carcinoma.
Hoogland H; Blijham G; Bron H; Eekhout A; van Geuns H; Haest J; Huiskes H; Kornman J; de Koning Gans H; Lalisang F
Prog Clin Biol Res; 1985; 201():213-5. PubMed ID: 3841592
[No Abstract] [Full Text] [Related]
4. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
[TBL] [Abstract][Full Text] [Related]
6. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.
Berek JS; Hacker NF; Lagasse LD; Poth T; Resnick B; Nieberg RK
Obstet Gynecol; 1984 Aug; 64(2):207-12. PubMed ID: 6539884
[TBL] [Abstract][Full Text] [Related]
7. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
[TBL] [Abstract][Full Text] [Related]
8. [Radical peritonectomy in 37 patients with stage II and III ovarian cancer].
Capretti PG; Zeppieri MC; Simonetti A; Rosato S; Lovotti D; Battaini A; Capretti G; Agnes Pradelli B
Minerva Chir; 2004 Jun; 59(3):233-41. PubMed ID: 15252388
[TBL] [Abstract][Full Text] [Related]
9. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP
Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy in the management of ovarian germ cell malignancies.
Schwartz PE
Obstet Gynecol; 1984 Oct; 64(4):564-72. PubMed ID: 6207473
[TBL] [Abstract][Full Text] [Related]
11. [Secondary cytoreductions in the treatment of ovarian cancers].
Zylberberg B; Dormont D; Janklewicz S; Daraï E; Madelenat P; Antoine JM
Gynecol Obstet Fertil; 2000 Feb; 28(2):127-36. PubMed ID: 10758587
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
[TBL] [Abstract][Full Text] [Related]
13. Stage III-IV epithelial carcinoma of the ovary: is the second-look operation of any value for the patient?
Atad J; Bornstein J; Steiner M; Weill S; Lurie M; Abramovici H
Isr J Med Sci; 1988 Nov; 24(11):660-3. PubMed ID: 3215758
[TBL] [Abstract][Full Text] [Related]
14. Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients.
Peccatori F; Bonazzi C; Chiari S; Landoni F; Colombo N; Mangioni C
Obstet Gynecol; 1995 Sep; 86(3):367-72. PubMed ID: 7651644
[TBL] [Abstract][Full Text] [Related]
15. [Survival in ovarian cancer treated in a gynecological department of a central hospital].
Dragsted NO; Nørgaard M; Bøsling KB
Ugeskr Laeger; 1997 May; 159(20):3003-9. PubMed ID: 9190729
[TBL] [Abstract][Full Text] [Related]
16. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
17. Peptichemio in pretreated patients with ovarian cancer.
Paccagnella A; Tredese F; Salvagno L; Brandes A; Sileni VC; Daniele O; Fornasiero A; Fosser V; Nicoletto O; Maggino T
Cancer Treat Rep; 1985 Jan; 69(1):17-20. PubMed ID: 3155650
[TBL] [Abstract][Full Text] [Related]
18. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
[TBL] [Abstract][Full Text] [Related]
19. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
20. Therapy of advanced ovarian juvenile granulosa cell tumors.
Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
